Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stapokibatrt in children with atopic dermatitis
NCT07106372Phase 3Not yet recruiting
- Sponsor
- Keymed Biosciences
- Start
- Sep 2025
- Primary completion
- Feb 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of stapokibart in atopic dermatitis (AD), sponsored by Keymed Biosciences. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
stapokibart
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT07106372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07106372.